Listed by the USPTO as GORDON, MELENIE LEE
Tech Center 1600 • Art Units: 1621 1629 1651 1655 1657
This examiner grants 22% of resolved cases
GORDON, MELENIE LEE is assigned to tech center 1600 and art unit 1621. The profile shows 219 resolved cases, a 22.4% allowance rate, and a median of 1171 days to allowance. The recorded outcome suggests that applicants should prepare for sustained prosecution and should not assume that an allowance will follow quickly from initial examination.
The interview lift is 45.1%, associating interviews with improved allowance outcomes in the available data. Counsel may consider interviews as a central part of response planning, especially when proposed amendments can be discussed with precision. The listed companies are Hoffmann-La Roche Inc., Board of Regents of the University of Texas System, and Novozymes A/S. The firms are BIRCH STEWART KOLASCH & BIRCH, LLP, HULTQUIST IP, and MORSE, BARNES-BROWN & PENDLETON, P.C.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18441878 | E3 UBIQUITIN LIGASE (UBE3A) PROTEIN TARGETS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17331723 | ELECTROANALYTICAL DETERMINATION OF LEUKOCYTE ESTERASE | Final Rejection | Board of Regents, the University of Texas System |
| 18840008 | METHOD FOR CARRYING OUT THE COMBINED OPERATION OF A BIOETHANOL PRODUCTION UNIT AND A BIOGAS UNIT | Non-Final OA | Novozymes A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy22.4% of resolved applications examined by Melenie Lee Gordon were allowed (219 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +45.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Melenie Lee Gordon took 1,171 days on average from filing to allowance.
Melenie Lee Gordon examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
